



## **InhaleRx Commences Manufacturing of IRX-211 for Ph2 Breakthrough Cancer Pain Trial**

**Melbourne, Australia 3 June 2025** - InhaleRx Limited (ASX:IRX), (**'the Company'** or **'InhaleRx'**), a clinical-stage drug development company specialising in inhaled therapies to address unmet medical needs, is pleased to announce the commencement of manufacturing for its lead investigational product, IRX-211, in preparation for its upcoming fully funded Phase 2 clinical trial targeting breakthrough cancer pain (**'BTcP'**).

Manufacturing of IRX-211 is being conducted by Ab Initio Pharma, a GMP-certified pharmaceutical manufacturing specialist based in Sydney, Australia. This marks a major operational milestone as the Company transitions from development to clinical supply readiness.

IRX-211 is a proprietary, inhaled cannabinoid formulation designed to deliver rapid onset pain relief. It has been specifically developed to address the unpredictable and severe nature of BTcP, with the aim of offering patients fast, safe and reliable pain relief.

InhaleRx's CEO, Darryl Davies, commented, *"The start of manufacturing for IRX-211 is a pivotal achievement for InhaleRx and a testament to the focus and discipline of our clinical and technical teams. This milestone brings us one step closer to delivering a much-needed solution for patients suffering from breakthrough cancer pain. With a strong manufacturing partner in Ab Initio and a clear path ahead, we remain on track with our clinical timelines."*

InhaleRx will continue to update the market as the clinical program advances toward first patient in.

This announcement has been authorised for release by the Board of InhaleRx Limited.

### **For further information:**

[www.inhalerx.com.au](http://www.inhalerx.com.au)

James Barrie, Company Secretary  
Phone +61 3 8678 4091

### **About InhaleRx Limited (ASX: IRX) – [www.inhalerx.com.au](http://www.inhalerx.com.au)**

InhaleRx Limited is an Australian clinical stage drug development company which is developing rapid onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The Company has secured a funding facility of up to \$38.5m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain (**'BTcP'**), and IRX-616a to treat Panic Disorder.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for InhaleRx and the Company's shareholders, as the clinical indications under investigation have been carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps where there's currently mismatched treatment options that can carry dependency concerns.